Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Siempos II, et al. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361992 Free PMC article.
High-dose corticosteroids adjusted to oxygen requirement and monitoring of serum C-reactive protein to improve outcome of non-critically ill COVID-19 patients: the CocAA-CoLa Plus Study.
Kevorkian JP, Vandiedonck C, Laganier J, Lopes A, Burlacu R, Feron F, Chaix ML, Sene D, Riveline JP, Gautier JF, Megarbane B. Kevorkian JP, et al. Among authors: burlacu r. Minerva Med. 2023 May 11. doi: 10.23736/S0026-4806.22.08326-4. Online ahead of print. Minerva Med. 2023. PMID: 37166204 No abstract available.
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial.
Zuily S, Lefèvre B, Sanchez O, Empis de Vendin O, de Ciancio G, Arlet JB, Khider L, Terriat B, Greigert H, Robert CS, Louis G, Trinh-Duc A, Rispal P, Accassat S, Thiery G, Montani D, Azarian R, Meneveau N, Soudet S, Le Mao R, Maurier F, Le Moing V, Quéré I, Yelnik CM, Lefebvre N, Martinot M, Delrue M, Benhamou Y, Parent F, Roy PM, Presles E, Goehringer F, Mismetti P, Bertoletti L, Rossignol P, Couturaud F, Wahl D, Thilly N, Laporte S; COVI-DOSE investigators. Zuily S, et al. EClinicalMedicine. 2023 Jun;60:102031. doi: 10.1016/j.eclinm.2023.102031. Epub 2023 Jun 9. EClinicalMedicine. 2023. PMID: 37350990 Free PMC article.
No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.
Burlacu R, London J, Fleury A, Sené T, Diallo A, Meyssonnier V, Zeller V, Galland J, Huscenot T, Rubenstein E, Trouiller P, Amathieu R, Kutter J, Blondeel D, Lejour G, Mouly S, Lidove O, Wladimir M, Sène D. Burlacu R, et al. Medicine (Baltimore). 2021 May 28;100(21):e26023. doi: 10.1097/MD.0000000000026023. Medicine (Baltimore). 2021. PMID: 34032722 Free PMC article.
33 results